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Abstract The theory of resonance in population per-
sistence proposes that the survival of a population that 
is exposed to externally inflicted loss processes (distur-
bances) during part of its life cycle is dependent on the 
relation between the average period of the disturbances 
and the average generation time of the population. This 
suggests that the size of a population can be controlled 
by manipulating the period between external disturbanc-
es. This theory, first formalized in a study of intertidal Red 
Sea mollusks exposed to periodic storms, has been found 
to apply to such seemingly disparate phenomena as the 
spread of a pathogen among susceptible individuals and 
the response of malignant cancer cells to chemotherapy. 
The current article provides a brief review of the evolution 
of the resonance theory into a tool that can be applied to 
designing vaccination policies – specifically, in prepared-
ness for bio-terrorism attacks – and in personalized medi-
cine. A personalized protocol based on the resonance the-
ory was applied to a cancer patient, stabilizing his tumor 
progression, relieving his hematopoietic toxicity, and ex-
tending his survival.
A few short decades ago, mathematics and biology were 
considered to be entirely disparate fields: biology was a 
“wet science” with little use for theory. Yet nowadays it is 
difficult to imagine the field of biology without mathe-
matical modeling. Models enable researchers to simulate 
the progression of cancer and other diseases on a cellu-
lar level, and to predict the response of patients to famil-
iar and prospective treatment regimens (1). In epidemiol-
ogy, mathematical models are used to predict how new 
pathogens will spread in populations of unvaccinated in-
dividuals (2). Clearly, a mathematical model can provide 
practical insights into the specific phenomena it addresses 
–indicating, for example, how frequently a drug should be 
administered, or the number of people who are expected 
to contract a new disease. But perhaps the most success-
ful models are those that provide a deeper understanding 
of the phenomena at hand, enabling researchers to draw 
fundamental conclusions regarding the nature of biologi-
cal systems.
This article discusses how mathematical modeling re-
vealed a single physical process – the resonance phe-
nomenon in population persistence – underlying a large 
number of biological processes that seemed entirely un-
related to one another, aside from the fact that they were 
subject to the influence of external forces. Agur and De-
neubourg (3) first discovered this phenomenon when 
they developed a mathematical model to investigate how 
mollusk populations in the Red Sea are able to persist de-
spite periodically being decimated by severe storms. Agur 
and Webb later expanded the model into a general theory 
(4-6) and, further, asserted that the resonance phenom-
enon characterized the spread of pathogens in a human 
population under vaccination, as well as the progression 
of various types of cancer under therapy. As will be shown 
below here, this insight enabled Agur et al to suggest de-
finitive strategies for influencing these biological process-
es. In particular, Agur et al discussed how policy makers 
can devise resource-efficient vaccination strategies in the 
face of epidemics and even bioterrorism threats (7-9). Ad-
ditional studies, relying on the same theory, have theoreti-
cally and experimentally shown that a chemotherapeutic 
dosing schedule can be planned such that drug efficacy is 
maximized and toxicity is minimized (10,11). These stud-
ies indicated that the optimal dosing schedule for a given 
patient is dependent on specific characteristics of the pa-
tient’s internal biological processes, suggesting that drug 
regimens ought to be determined for each patient on an 
individual level. This notion, which has since received 
substantial theoretical support, was tested empiri-
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cally both in cellular and murine experiments and in the 
clinic (10-12).˝Drawing from resonance theory, Gorelik et al 
(12) designed a personalized dosing regimen for a cancer 
patient whose treatment had previously been unsuccess-
ful, and the new schedule substantially improved the pa-
tient’s clinical outcomes. The current article provides a brief 
review of the evolution of the resonance theory into a tool 
which can be used in determining vaccination policies – 
and, specifically, in preparedness for bio-terrorism attacks 
– and in personalized medicine.
THE THEORY OF RESONANCE IN POPULATION 
PERSISTENCE
When a system is oscillating at a given frequency, even 
small periodic driving forces – if applied at the correct fre-
quency – can yield large amplitudes of oscillation. This is 
called resonance. To understand how this works, imagine 
a mother pushing her child on a swing: if she pushes the 
swing only once, the swing will continue to go back and 
forth at a natural frequency (or period). If she pushes the 
swing every time it goes back, at the peak of its trajectory, 
it will continue to go back and forth at the same natural fre-
quency, but the amplitude of the swing will increase from 
push to push. Notably, this will occur even if the mother 
gets tired and only pushes the swing every second time 
it goes back, or every third time – that is, the amplitude 
of the swing will continue to increase if the period of her 
push divided by the period of the swing is a whole num-
ber. But if she pushes the swing at times that are complete-
ly different from the period of the swing – eg, at random 
(such that the period of the push divided by the period of 
the swing is an irrational number) – the amplitude of the 
swing will slowly go down to a minimum.
Most biological systems can be characterized as “oscil-
lating,” that is, they entail cyclicality. Individuals are born 
into a population, reproduce, and die. This is true for mol-
lusks, healthy somatic cells, and cancer cells alike. The 
process by which an epidemic spreads in a population 
can also be characterized as oscillatory: a pathogen is in-
troduced into a population, people contract the disease 
and spread it to others, and the number of infected in-
dividuals rises to a maximum, and then gradually dimin-
ishes as people acquire immunity (or die). Yet a few years 
down the line, if no additional action is taken, the dis-
ease resurfaces, as new non-immune people enter the 
population (2). The oscillating nature of biological sys-
tems suggests that we can exploit the phenomenon 
of resonance to manipulate their dynamics. That is, 
by applying force at opportune moments, it is possible 
to enhance the growth of desirable populations (such as 
healthy tissue cells), or to eliminate undesirable popula-
tions (such as cancer cells).
Agur (4) and Agur and Deneubourg (3) were the first to 
mathematically model and prove the existence of the 
resonance phenomenon in population persistence. Their 
models aimed to shed light on the means by which popu-
lations are able to survive despite being periodically ex-
posed to environmentally inflicted loss processes, or “ca-
tastrophes.” Agur and Deneubourg (3) focused on the case 
of intertidal Red Sea mollusks, which are periodically ex-
posed to harsh storms. These storms obliterate the adults, 
which are sessile on the rocks, but they do not harm the 
plankton-like juveniles, which drift freely in the sea. The au-
thors investigated the relationship between the durations 
of such catastrophes and the duration of the resistant, ju-
venile stage of the mollusk life cycle. Analysis of their mod-
el showed that the population was most vulnerable to ran-
domly occurring catastrophes (ie, the population’s time to 
extinction is minimized) if the ratio between the average 
generation time in the population and the average period 
of the catastrophe is irrational (Figure 1). Agur (4) extend-
ed this model into a general theory, asserting that the sur-
vival of any population that is susceptible to imposed loss 
processes during part of its life cycle is dependent on the 
relation between the average period of the disturbances 
and the duration of the life cycle of the population. Res-
FIgURE 1. A schematic illustration of the resonance phenom-
enon. Survival of a population is plotted as a function of the 
ratio between the inherent population periodicity and the 
disturbance periodicity, τ/δ+ω, where τ is the generation time 
of the population and δ+ω stands for the average period of 
the disturbance process.
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onance – that is, maximum population growth – occurs 
when the average period of the imposed loss process is an 
integer or fractional multiple of the inherent period of the 
population. This suggests that the size of a population can 
be controlled by manipulating the duration of the period 
between external disturbances. More generally, a dynamic 
process that oscillates in the number of individuals who 
are susceptible to a given disturbance can be efficiently 
controlled by imposing recurring disturbances of a prede-
termined period.
USINg THE RESONANCE PHENOMENON TO IDENTIFY 
OPTIMAL VACCINATION POLICIES
Pulse vaccination policy
A key objective of epidemiology, the study of the patterns 
of disease spread in populations, is to develop optimal vac-
cination policies against infectious diseases. In this domain, 
acknowledgment of the resonance phenomenon in popu-
lation persistence can have far-reaching implications.
The mathematical SEIR (Susceptibles, Exposed, Infectious, 
Resistant) model is a straightforward means of describing 
the spread of an infectious disease in a population (2). This 
model divides the population into four compartments: (i) 
Susceptible individuals (S), who have not yet been infected 
and are vulnerable to the disease; (ii) exposed individuals 
(E), who have been infected but cannot yet infect others; 
(iii) infectious individuals (I), who can infect others; and (iv) 
resistant individuals (R), who cannot be infected by the dis-
ease. Individuals can become resistant – ie, immune – ei-
ther by contracting and overcoming the disease, or by be-
ing vaccinated.
When applied to a large unvaccinated population over a 
long period of time, the SEIR model describes a pattern of 
recurring epidemics of diminishing scope (Figure 2). In a 
single epidemic, the number of susceptible individuals in-
creases quickly as people are exposed to the disease and 
then decreases through the natural process of infection 
and acquisition of natural immunity, until the number of 
susceptible people becomes so small that it practically 
prevents further contact between susceptible and infec-
tious persons, thus leading to the termination of the cur-
rent epidemic. However, as new people enter the popu-
lation (ie, are born into the population or enter through 
immigration), the number of susceptible people grows 
once again, and when its density is sufficiently high, a new 
introduction of the pathogen will cause a new epidemic 
to flare up. In this way, epidemics of infectious diseases be-
come an oscillatory process. The actual trajectory of a dis-
ease in a given population – that is, how frequently it re-
curs and the number of individuals who will be infected in 
each outbreak – is dependent on the characteristics of the 
disease (eg, its virulence, the duration of time for which it 
is contagious) as well as the characteristics of the popula-
tion (eg, diseases might be more likely to spread in large, 
crowded cities than in rural areas where people have little 
exposure to one another). These qualities are all captured 
in a single model parameter called the basic reproduction 
rate of the epidemic (2).
According to the resonance theory outlined above, it 
seems that the periodic dynamics of disease can be effi-
ciently combated by a periodic vaccination policy (to be 
denoted pulse vaccination policy). In this case, the popula-
tion being affected by the loss process is the population of 
susceptible individuals: this population is “diminished” by 
vaccination, because vaccinated individuals cease to be 
susceptible and become resistant.
In 1993, Agur et al developed a mathematical model with 
the goal of proposing a policy that would eradicate mea-
sles in Israel (9). The vaccination policy in place at the time 
was a typical cohort-based vaccination policy, ie, children 
were vaccinated once at the age of 15 months and again 
FIgURE 2. Simulation results of an adapted SEIR model (8): 
number of infected individuals over time when smallpox is 
introduced into the Israeli population by one infective carrier. 
Thick line: natural disease dynamics (no vaccination strategy 
is implemented). Thin line: disease dynamics after implemen-
tation of one-time mass vaccination strategy (population is 
vaccinated at maximum capacity for three days following the 
attack).
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at the age of 6 years. However, this policy was insufficient 
to prevent measles from recurring every five years or so. 
Agur et al showed that vaccination of 1-7-year-olds every 
five years would prevent epidemics from recurring. Shulgin 
et al analyzed the model and showed that the pulse vacci-
nation policy can lead to eradication of the epidemic, also 
withstanding seasonal variation (13). A strategy based on 
proposition by Agur et al was successfully implemented by 
the Israeli Ministry of Health.
An interesting observation that emerges from the study by 
Agur et al is that, intuitively, it seems as if the entire popula-
tion should have been “covered” by the cohort-based vac-
cination policy that was in place. Yet herd immunity in the 
Israeli population was insufficient to prevent disease out-
break. This emphasizes that reality – in which many indi-
viduals are not vaccinated as a result of noncompliance, 
contraindications, or other factors – might not always cor-
respond to an intuitive understanding of which vaccina-
tion strategies should be effective. The mathematical mod-
el by Agur et al captured the recurrence of epidemics and 
showed that periodic vaccination of a small portion of the 
population was a more effective means of ensuring that 
the disease does not recur in the population.
Pulse vaccination in bioterrorism preparedness policies
The need to identify effective vaccination strategies be-
came particularly salient in the early 2000s when, follow-
ing the events of 9/11, bioterrorism suddenly became 
a serious concern. The US Centers for Disease Control 
and Prevention (CDC) was particularly concerned about 
the possibility of an outbreak of smallpox, owing to the 
ease of transmission of this agent, and the susceptibility 
to it in the previously unexposed population. A vaccine 
against smallpox (vaccinia) existed but was associated 
with significant adverse side effects (14). Furthermore, 
even if the population were to be vaccinated, little was 
known about how a smallpox bioterrorism attack would 
play out in a contemporary population. In particular, it 
was not clear what the disease’s actual basic reproduc-
tion rate would be, how the population would respond 
to an outbreak, how willing people would be to com-
ply with vaccination campaigns, and how much vaccine 
would be available.
Two strategies being considered by policy makers at 
the time, included preliminary vaccination (ie, vaccinat-
ing the population before an attack had actually hap-
pened) and post-attack mass vaccination – that is, 
vaccinating the entire population immediately after dis-
ease outbreak. Clearly, neither approach is ideal – prelimi-
nary vaccination risks “wasting” vast resources if no attack 
actually occurs. Post-attack mass vaccination – perhaps the 
most intuitive response to such an event – is likely to be 
impeded by mass hysteria and vaccine stockpile shortage. 
At that period, several mathematical models were devel-
oped in order to analyze the problem of a potential small-
pox outbreak in the human population and identify an ef-
fective vaccination policy (14-17). However, some models 
contradicted the recommendations of others, owing to a 
fundamental lack of knowledge regarding the characteris-
tics of the virus. More worryingly, these models focused on 
preventing a single epidemic but did not evaluate what 
would happen several years down the line. Agur et al (8) 
showed, using the SEIR model, that preliminary vaccina-
tion and one-time mass vaccination strategies would not 
actually prevent epidemics from recurring several years fol-
lowing an initial attack. This might seem counterintuitive, 
given that these vaccination policies claim to “cover every-
one” – yet, as discussed in the previous subsection, and as 
shown through the dynamics of the SEIR model (Figure 2), 
reality does not always correspond to intuition.
Agur et al proposed a pulse vaccination policy, wherein 
once every few months or years following disease out-
break, a certain percentage of the population is vaccinat-
ed. Under this policy, the actual details of the vaccination 
strategy – namely, the percentage of the population vac-
cinated and the period between vaccination campaigns – 
are determined after the smallpox pathogen has been in-
troduced into the population, when more information on 
the behavior of the disease is available. They showed that 
a pulse strategy would not only be more effective over the 
long term compared with preliminary or one-time mass 
vaccination but would also be more practical: the suc-
cess of the strategy is not dependent on full and immedi-
ate compliance and vaccine availability. Furthermore, the 
strategy offers flexibility, which is crucial in situations char-
acterized by such high uncertainty. Specifically, there ex-
ists a critical ratio between the percentage of the popula-
tion vaccinated per day and the inter-pulse interval, above 
which the pulse vaccination strategy will suffice to prevent 
subsequent epidemics. As long as this ratio is maintained, 
the actual period and the number of people vaccinated 
can be adjusted according to actual compliance or vaccine 
availability; for example, if fewer people than desired are 
vaccinated during an individual campaign, it is possible to 
compensate by shortening the time period until the next 
campaign (Figure 3).
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USINg THE RESONANCE PHENOMENON TO IDENTIFY 
PERSONALIZED CHEMOTHERAPY REgIMENS
Resonance in chemotherapy
Cancer is treated primarily by cell-cycle phase-specific che-
motherapeutic drugs. These drugs destroy cells that are in 
a specific proliferative phase of the cell-cycle, whereas cells 
in other cycle phases, quiescent or non-proliferative cells, 
are resistant to treatment. After treatment is administered, 
some unharmed cells become proliferative, and the drug-
susceptible cell population is replenished. Clearly, then, 
like populations of inter-tidal organisms, or populations of 
individuals who are susceptible to an infectious disease, 
drug-susceptible cancer cell populations are characterized 
by periodic dynamics. Thus, according to the resonance 
theory, these populations are likely to be efficiently con-
trolled through control of a periodic loss process inflicted 
by chemotherapeutic drugs. Likewise, when considering 
cancer treatment, one should also consider the healthy 
host cells, which are also adversely affected by treatment 
(in a cell-cycle-phase-specific manner). The resonance the-
ory suggests that it is possible to choose a dosing schedule 
– that is, a frequency of catastrophes – that will eliminate 
the population of malignant cells while maintaining the 
population of healthy cells at a maximum. Specifically, the 
dosing period should be a fractional multiple of the aver-
age cell-cycle duration of healthy host cells but not of the 
cell-cycle duration of cancer cells (10,18). This approach is 
a departure from the well-known “dose-dense” paradigm 
proposed by Norton and Simon (19). Norton and Simon ar-
gued that the efficacy of cancer therapy can be enhanced 
by increasing the dosing rate, for example, by applying the 
maximum tolerated dose and decreasing the inter-dosing 
intervals. This paradigm is based on the assumption that 
cancer growth obeys the Gompertz law (where population 
growth is described by a sigmoid function, growth being 
slowest at the start and end of a period), and that the rate 
of tumor regression induced by chemotherapy is propor-
tional to the growth rate of an untreated tumor of the same 
size (18,19). Although this paradigm has been used to treat 
cancer effectively (20), Norton and Simon never validated 
the Gompertz model, that is, they never checked whether 
in real life tumor growth actually obeys the sigmoid func-
tion comprising the Gompertz law, so that the dose-dense 
paradigm can be generalized.
The validity of the resonance-based approach has been 
supported both theoretically and empirically. Theoretical 
studies include, among others, those of Agur et al (6,10) 
and Dibrov et al (21), which modeled treatment of cancer 
with cell-cycle phase-specific drugs. These studies used 
highly simplified models of a cancer patient, assuming that 
tumor cells and target host tissues differed only in terms 
of their cell cycle parameters (all studies ignored the spa-
tial arrangement of these cells). This approach reduced the 
complex physiological and pathological dynamics of tu-
mor progression under different chemotherapy regimens 
into one essential variable: the ratio between the rate of 
tumor growth and the growth rate of healthy tissues.
FIgURE 3. Simulated outcomes of a pulse vaccination strategy implemented in Agur et al (8): cost (calculated according to the num-
ber of infected individuals, in addition to other factors) as a function of percent vaccination capacity utilized and interval between 
pulses (in days), assuming that the disease’s basic reproduction rate is 3. There is a critical ratio (diagonal contour) between capacity 
utilized and the interval, above which the strategy will be effective (shaded area) and below which costs rise suddenly.
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Arnon and Schechter (10) considered an abstract case in 
which drug efficacy was stepwise “infinite,” ie, all cells in 
the vulnerable cycle phases were instantly eliminated dur-
ing the fixed period in which the drug was effective, while 
no cells were affected during the drug-free interval. This 
model, which assumed stochastic inter-dosing intervals, 
showed a clear advantage for population growth when 
the period of the loss process coincided with an inherent 
population reproduction period. Cojocaru and Agur, (6) 
who also relied on a probabilistic dosing interval, consid-
ered a more realistic case, in which drug efficacy was “finite” 
and driven by drug decay kinetics. Analysis of this model 
provided explicit formulas for the growth or decay of the 
tumor cell population, which further supported the exis-
tence of the resonance phenomenon. Kheifetz et al (22) 
proved that the superior efficacy endowed by applying 
fully periodic drug regimens according to the Resonance 
Theory was steadily maintained over time.
Dibrov et al (21) relied on systems of deterministic differen-
tial equations (rather than on a stochastic approach) and 
showed that when the mean cell-cycle times of normal 
and tumor cells differ considerably, optimal drug sched-
ules can significantly improve therapeutic efficacy, when 
drug periodicity is close to the mean cell-cycle time of the 
normal population and is practically independent of the 
tumor cell-cycle parameters. In this case, identification of 
the optimal treatment regimen heavily depends on pre-
cise estimation of the mean cell cycle duration of both 
cancer and host cells.
In vitro and in vivo experiments have provided further 
support to the proposition that drug timing can be ma-
nipulated to minimize toxicity and maximize drug efficacy. 
In vitro experiments (10), in which cells were exposed to 
short pulses of cytosine arabinoside (ara-C) – an S-phase-
specific cancer drug – tested the dependence of cell pop-
ulation growth on the inter-dosing interval. Experimental 
results showed that, regardless of the total drug dose or 
the experimental procedures, drug schedules whose pe-
riodicity was an integer multiple of the average popula-
tion cell-cycle duration were associated with significantly 
higher population growth rates, as evaluated by rates of 
DNA synthesis.
Ubezio et al (11) investigated whether a resonance-based 
dosing approach could be feasible using the clinical 
methods available at the time. They administered short 
pulses of ara-C, with different dosing schedules, to 
lymphoma-bearing mice. The schedules varied in 
terms of the distributions of the inter-dosing intervals, 
and included stochastically-determined schedules; the 
total dose and total treatment duration were kept con-
stant across treatment conditions. Toxicity was evaluated 
by spleen weight, peripheral blood measurements, and 
the proportion of bone-marrow cells in the S-phase gate 
of the DNA content distributions. The observed response 
of mice to the administered treatment schedules showed 
that a schedule in which the duration of the inter-dosing 
intervals was random inflicted higher cytotoxicity com-
pared with a regimen of constant inter-dosing intervals, 
as reflected in bone marrow cells (see Figure 7 in [11]) and 
in mice survival (see Figure 9 in[11]). The experimental re-
sults suggest that myelotoxicity is minimized when the 
inter-dosing interval is a multiple of the inter-mitotic time 
of bone-marrow stem and progenitor cells, thereby sup-
porting model predictions (10).
In another study, Skomorovski and Agur (23) investigated 
the resonance phenomenon from another angle – appro-
priate timing of dosing schedules aimed at boosting the 
growth of healthy hematopoietic host cells rather than 
eliminating cancerous cells. The study focused on the hor-
mone thrombopoietin (TPO), also known as megakaryo-
cyte growth and development factor. This agent can po-
tentially be used to attenuate thrombocytopenia but is 
associated with severe immunogenicity, which limits its 
therapeutic use. The authors developed a mathematical 
model and a simulation tool that showed that platelet 
counts similar to those obtained with standard, immuno-
genic TPO dose scheduling can also be obtained with saf-
er periodic schedules of significantly reduced doses that 
are appropriately timed. Skomorovski et al (24) later vali-
dated this prediction in mouse and monkey experiments. 
Specifically, in a two-arm mouse experiment, they showed 
that platelet profiles obtained with a single intraperitoneal 
dosing of recombinant mouse TPO (17.5 µg/kg) resembled 
those obtained with a model-suggested periodic protocol 
of a much smaller dose (2 µg/kg on 4 consecutive days). In 
rhesus monkeys, treated by rhesus monkey recombinant 
TPO (5 µg/kg on 4 consecutive days), the suggested proto-
col yielded effective platelet stimulation with minimal im-
munogenicity, as demonstrated over prolonged applica-
tion (24,25)
Oncology personalization
A prevailing notion in oncology is that the progression of 
cancer in a given individual is difficult if not impossible to 
predict. Indeed, the manifestations of disease vary substan-
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tially – seemingly haphazardly – across different patients, 
owing to factors such as age, gender, diet, organ function, 
and genetic variability. It follows that a patient’s response 
to a given therapeutic regimen is also virtually impossible 
to predict (26,27). Current paradigms of clinical trials do lit-
tle to address this issue: new drug candidates are admin-
istered through exactly the same protocol (or through a 
limited number of protocols) to large populations of pa-
tients and are approved for further consideration if they 
yield statistically significant improvement, that is, enough 
patients are benefitted. As a result, drug candidates that 
might suit small fractions of the patient population, or that 
might yield benefit to certain patients if administered in 
a specific protocol that differs from protocols tested slip 
through the cracks.
Although cancer and response to cancer therapy are in-
deed highly individual, they are not necessarily unpredict-
able. Our working hypothesis is that the important patho-
logical processes are relatively consistent across patients 
and can be described by the same formulas. But, although 
the general formulas are similar in all patients, the values of 
the parameters in these formulas, that is, the various reac-
tion rates are patient-specific. The different reaction rates, 
typifying the pathophysiological processes in each patient, 
are the source of variation in the response to treatment. 
As discussed above, in order to design an effective drug 
therapy approach for an individual patient – it is important 
to know the patient-specific reaction rates of the influen-
tial pathological and physiological processes (eg, cell cycle 
duration when chemotherapy is involved).
Once certain clinical data have been collected, mathemati-
cal models can be used to estimate the patient’s individu-
al parameter values and to identify the optimal treatment 
regimen for him or her. Such models can take into account 
not only the patient’s characteristics but also the specific 
aim of the treatment: for example, in some cases the clini-
cian may seek to aggressively eliminate the tumor, even at 
the risk of side effects, whereas in others it may be sufficient 
merely to slow down tumor progression while prioritizing 
avoidance of toxicity. The use of mathematical models can 
transform the process of identifying an effective treatment 
regimen from one of trial and error into a rational decision-
making process (10,18).
A case study by Gorelik et al (12) demonstrates the cru-
cial role of personalization in the design of effective res-
onance-based dosing regimens. The researchers carried 
out their study in a single patient, a 45-year-old white 
man suffering from mesenchymal chondrosarcoma 
(MCS). MCS is a rare disease (accounting for about 1% of 
chondrosarcomas) with a 5-year survival rate of 55%, for 
which there is currently no efficacious treatment. The pa-
tient had undergone aggressive chemotherapy with if-
osphamide, cisplatin, and etoposide for six cycles, VACA 
(vincristine, doxorubicin, cyclophosphamide, and dactin-
omycin) for 2 cycles, and sunitinib p.o. for 8 weeks. De-
spite this treatment regimen, the cancer continued to 
spread, with additional metastases appearing in the liv-
er and bone. Furthermore, as a result of the aggressive 
treatment, the patient suffered severe myelo-suppression 
with pancytopenia.
To collect clinical data regarding the progression of the 
cancer, the researchers xenografted tumor samples, ob-
tained from the patient’s lung, into mice. They measured 
tumor volume over time and analyzed gene expression 
in the xenografted tumors as well as in the patient’s me-
tastases. Once tumors grew to 50-150 mm3 in size, ani-
mals were pair-matched by tumor size into treatment 
and control groups, and treatment animals were admin-
istered drugs by different monotherapy or combination 
regimens. In parallel, a general growth model of vascular 
tumors was adjusted to describe the MCS xenograft dy-
namics. This was done by evaluating the parameters of tu-
mor growth dynamics in the untreated mice. Using the 
xenograft-adjusted model, the growth of the MCS xeno-
grafts and their response to various drug therapies was 
simulated, in conjunction with the pharmacokinetics and 
the pharmacodynamics of the pertinent drugs, and with 
the applied dosing regimens. The developed model was 
used to evaluate tumor growth inhibition (TGI) in the xe-
nografted MCS patient tumors, by simulating different 
monotherapies and combinations of two or three cytotox-
ic and anti-angiogenic drugs (TGI is a conventionally-for-
mulated measurement of the change, over time, in tumor 
size under a particular drug protocol, as compared to the 
change in untreated tumors over the same time). Model 
simulations enabled predictions of the differences in TGI 
which would be inflicted by the different drug protocols, 
applied to the MCS patient’s xenografts. The combination 
of bevacizumab and docetaxel was predicted to be most 
efficacious in inhibiting the growth of tumors originating 
at the MCS lung metastasis (Figure 4). Model predictions 
were compared to the experimentally observed values, 
showing prediction accuracy of 87.1%.
The personalized MCS xenograft model was the basis 
for the human model. Model parameters were up-
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scaled by comparing experimentally evaluated gene ex-
pression levels of several growth factors in the patient to 
those in mice and adjusting parameter values according-
ly. Literature data on the involved drugs were employed 
to model their pharmacokinetics in this MCS patient. 
Thereafter, a mathematical MCS patient model was simu-
lated to predict the patient’s response to many different 
docetaxel/bevacizumab combination regimens. Simula-
tion results suggested that a regimen containing bevaci-
zumab applied i.v. in combination with once-weekly doc-
etaxel would be more efficacious in the MCS patient than 
any other simulated schedule. Indeed, weekly docetaxel 
in the patient stabilized the metastatic disease and miti-
gated pancytopenia. This result was not surprising. The 
knowledge that the major processes involved in solid tu-
mor progression have periodic patterns, in conjunction 
with the universality of the resonance phenomenon, im-
ply that there exists an optimal docetaxel regimen of a 
characteristic period. Docetaxel is a microtubule stabi-
lizing drug. In addition to its cytotoxicity against tumor 
cells, it also exhibits antiangiogenic properties when 
used at low doses, by inhibiting endothelial cell pro-
liferation, migration, and tube formation (28). Gore-
lik et al conjectured that angiogenesis was the force that 
drove the efficacy of docetaxel.
In order to apply the above theoretical results in treatment 
personalization, it is important to verify that, indeed, the 
superiority of the once-weekly docetaxel, as compared to 
the standard tri-weekly regimen, is determined by the clin-
ical angiogenic parameters of the individual patient. To this 
end, Gorelik et al (12) formulated an arbitrary function of 
the kinetic rate of new vessel formation, as influenced by 
vascular endothelial growth factor (VEGF) secretion, den-
sity of VEGF receptors, etc (denoted angiogenesis scaling 
factor and representing the intensity of angiogenesis). By 
simulating in the mathematical MCS model virtual patients 
carrying different values of the Angiogenesis Scaling Fac-
tor, they could test the potential effect of angiogenesis 
on the efficacy of docetaxel with or without bevacizum-
ab, as measured by TGI effect over time. Doing so, they 
could show that superiority of the one-weekly docetaxel 
regimen, over the tri-weekly regimen is a non-monotonic 
function of the angiogenic scaling factor (Figure 3B in[12]). 
This result, demonstrating the resonance phenomenon in 
the effects of a drug on the progression of a vascular tu-
mor, shows the importance of the dosing period in the ef-
ficacy of a treatment regimen and provides further sup-
port to the existence of the resonance phenomenon in 
human cancer.
In general, the case study by Gorelik et al (12) points to 
the enormous potential of personalization in the design 
of treatment regimens that take resonance into account, 
particularly in the context of rare diseases such as MCS, 
for which current clinical trial paradigms are particularly 
ill-suited. As yet, while personalized medicine is gradually 
gaining recognition, individual clinicians still do not exploit 
anywhere near its full potential in practice.
CONCLUSION
Mathematical modeling has revealed the resonance phe-
nomenon in population persistence, whereby small exter-
nal forces applied to an oscillating biological system can 
produce large effects on the size of the population – pro-
vided that the period of these forces is synchronized with 
the period of the population. First identified in the con-
text of intertidal mollusks in the Red Sea, the resonance 
phenomenon has been shown to characterize seemingly 
dissimilar phenomena such as the spread of pathogenic 
disease in a population as well as cancer progression, or 
hematopoiesis. In epidemiology, policy makers can achieve 
FIgURE 4. Mathematical model predictions of tumor growth 
inhibition (TgI). The drug protocols that were simulated are 
shown at the bottom of each histogram bar: B/Doc denotes 
bevacizumab, 10 mg/kg, IV, Q3Dx10 +docetaxel, 25 mg/kg, IV, 
Q7Dx3; B/Doc/g denotes bevacizumab, 6.7 mg/kg, IV, day 1,8 
+ docetaxel, 25 mg/kg, IV, Q7Dx3 + gemcitabine, 160 mg/kg, 
IV infusion, 24 hours (single dose); S denotes sunitinib, 40 mg/
kg, PO b.i.d x28; B/D denotes bevacizumab, 5 mg/kg, IP, Q4Dx6 
+ docetaxel, 3 mg/kg, IV, QDx8; B/Sor denotes bevacizumab, 5 
mg/kg, IP, Q4Dx6 + Sorafenib, 85 mg/kg, PO, QDx10.
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cost savings and substantially improve efficacy by adopt-
ing a “pulse” vaccination policy, which is vaccinating small 
fractions of the population at specific intervals, instead of 
adopting a cohort-based policy or a one-time mass vac-
cination policy. In the case of cancer, a resonance-based 
chemotherapeutic approach, designed according to the 
patient’s individual characteristics, can substantially limit 
tumor progression while simultaneously avoiding damage 
to healthy cells. This theory holds tremendous practical 
implications as well as broader significance: it shows that, 
fundamentally, biological domains that seem completely 
unrelated to one another are actually very similar.
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